Posts tagged “Pozen”

May 8

Pozen migraine drug licensed to Desitin for commercialization in Europe

Pozen The migraine headache treatment developed by Pozen now has a partner for commercialization in Europe.

May 1

Pozen losses increase but arthritis drug royalties grow

Pozen The Chapel Hill-based drug firm reports a loss of $8.4 million for the first quarter, up from $5.7 million a year ago. However, sales of the arthirtis drug Vimovo are growing.

April 30

Pozen runs into a headache with FDA over safer aspirin

Pozen's headache During a recent meeting with the FDA to discuss its submission, the agency suggested the Chapel Hill-based company also seek approval for the drug at a lower dose

Updated March 22

Pozen shares surge on aspirin therapy trial news

The Chapel Hill-based pharmaceutical firm says its compound redcues gastric ulcers in two Phase 3 trials of patients who are taking aspirin daily. Pozen plans a new drug application in the third quarter. PLUS: Two board memebers leaving.

Diagram from Pozen presentation about PA technology Diagram from Pozen presentation about PA technology

December 22, 2011

Pozen strikes manufacturing pact with Patheon for heart drug

Patheon logo Pozen's new cardiovascular drug does not even have a name yet, but it has a manufacturer to produce it once it gets U.S. Food and Drug Administration approval.

November 28, 2011

Pozen's $75M deal - It's all about cash for product pipeline

Treixmet The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John Platchetka

Updated November 28, 2011

Pozen sells royalty rights to migraine drug for $75M

Treixmet Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan.

Updated November 6, 2011

Pozen CEO criticizes partner AstraZeneca for slow drug sales

Pozen "Although last quarter's U.S. net sales were up from the second quarter, the $13.4 million year to date total is well below what we think Vimovo is capable of selling so AstraZeneca has work to be done to make that better," John Platchetka says.

November 3, 2011

Tech earnings: Pozen, DexOne, Biocryst, Furiex, Targacept

Earnings It's been a busy earnings week, and five North Carolina firms all reported losses.

September 8, 2011

Losers in Treximet patent decision are appealing

Pozen A securities filing by patent-holder Pozen says that generic drug-makers are appealing a ruling by a judge in that Pozen had exclusive rights to Treximet.

Tags: Pozen, GSK
Updated August 16, 2011

Pozen names exec for customer development

Pozen The Chapel Hill-based pharmaceutical firm looks to boost its own pipeline of products.

August 8, 2011

What a relief - Pozen prevails in patent fight

Pozen Pozen had sued the Par, Alphapharm and Dr. Reddy's claiming that those generic product infringe on its three migraine drug patents. The litigation was consolidated into one suit that was tried last October.

July 22, 2011

Pozen forms advisory board for thoughts on digital development

Pozen The Chapel Hill-based pharmaceutical firm is seeking advice about how to revolutionize drug industry marketing and development.

Member Center

The Skinny: A Blog by Rick Smith

Videos

 
  • [VIDEO]

    Could Facebook cue tech bubble?

  • [VIDEO]

    Facebook 101: Examining a…

  • [VIDEO]

    Buffett won't join Facebook IPO mania

  • [VIDEO]

    Japan's tech titans post record losses

  • [VIDEO]

    FBI study reveals cyber crime trends

  • [VIDEO]

    Community collaborates for Triangle Wiki

  • [VIDEO]

    Video game conference is strictly…

  • [VIDEO]

    Re-program speed dial before Saturday

  • [VIDEO]

    Red Hat exec talks about company's $1B…